Crystallographic Fragment Screening and Structure-Based Optimization Yields a New Class of Influenza Endonuclease Inhibitors
about
Structural analysis of H1N1 and H7N9 influenza A virus PA in the absence of PB1The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug DesignCompounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virusThe specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?Replication-competent fluorescent-expressing influenza B virusProgress of small molecular inhibitors in the development of anti-influenza virus agents.Influenza A and B virus intertypic reassortment through compatible viral packaging signals.Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: inhibitors of influenza A endonuclease.Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials.Exploring the influence of the protein environment on metal-binding pharmacophores.Replication-competent influenza A viruses expressing a red fluorescent protein.Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.Functional Constraint Profiling of a Viral Protein Reveals Discordance of Evolutionary Conservation and FunctionalityA binding hotspot in Trypanosoma cruzi histidyl-tRNA synthetase revealed by fragment-based crystallographic cocktail screens.Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery.Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors.Structures of endothiapepsin-fragment complexes from crystallographic fragment screening using a novel, diverse and affordable 96-compound fragment library.Fragment-Based Identification of Influenza Endonuclease Inhibitors.Rapid experimental SAD phasing and hot-spot identification with halogenated fragments.Tuned by metals: the TET peptidase activity is controlled by 3 metal binding sites.N-acylhydrazone inhibitors of influenza virus PA endonuclease with versatile metal binding modes.Antiviral strategies against influenza virus: towards new therapeutic approaches.Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza.Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo.Protein-Structure Assisted Optimization of 4,5-Dihydroxypyrimidine-6-Carboxamide Inhibitors of Influenza Virus Endonuclease.A Bioinorganic Approach to Fragment-Based Drug Discovery Targeting Metalloenzymes.
P2860
Q27684927-BFBFC500-5C05-41F4-81F4-9B4EA4F544A5Q28071809-AC9D2808-53AB-4E19-B4EB-4036E3BFBA7AQ28084005-B3D12FCC-0597-49BD-B5D1-41636ACD1866Q28251512-8E259D2E-3F2C-4543-8258-FF0DCCA67303Q28387786-793752FB-D3E6-493C-8ED7-7B5A13079B99Q30234943-4AB2F541-7B11-4EA7-BAC1-8DECB96B00D4Q30364518-20ACC623-A5F2-4F94-B56F-0CF6F12F8CA7Q30366846-4257E3BE-2F32-4E54-9CF2-A5214A7E9BB8Q30781853-F9F510A6-3D09-4B56-A587-F5A246DE50C2Q34104343-8E25C8FD-5688-4D8F-8357-3B51512831EFQ35071285-1EECAEC4-9644-4551-BC5C-ED01946D6B70Q35592514-1358D6BC-F296-4A7B-B328-2D091A3A99C7Q35680145-CFA3CC50-1E21-471E-902E-A95B3BC2570AQ35739221-B5052A15-0BD7-4212-B7A7-B73FFD8AB61AQ35848043-1675C87D-33EF-4A53-B510-D674E671C029Q35960631-7C8D4252-2004-48D1-B9D9-922D65F62FEEQ36006936-BCCD9475-D083-46C8-B8B1-EBE70F35BDB1Q36049626-17C0599E-4E4B-4E40-A925-3661C4BE9A92Q36438686-A0C9D1FA-C7DC-43DB-96D0-CE9096C2C1F2Q36555459-53997377-14B8-4EBE-814E-F1D26C275C4EQ37166751-5D888426-C4DA-4453-ABD9-9159DD53AFBDQ38202012-90F51F9A-5E5D-4972-9632-CDB062DE3A35Q38384758-BC910C44-52ED-446E-93CF-70DACD6A7B95Q40052241-60668AD2-EDED-4741-96E8-BD000BEC3114Q45323667-1561574D-FFA0-4101-BDD9-BCE874E5668AQ45938767-559529DE-4AD5-4FAF-83C1-465CB6D6268D
P2860
Crystallographic Fragment Screening and Structure-Based Optimization Yields a New Class of Influenza Endonuclease Inhibitors
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@ast
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@en
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@nl
type
label
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@ast
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@en
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@nl
prefLabel
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@ast
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@en
Crystallographic Fragment Scre ...... luenza Endonuclease Inhibitors
@nl
P2093
P2860
P3181
P356
P1433
P1476
Crystallographic fragment scre ...... luenza endonuclease inhibitors
@en
P2093
Ajit K Parhi
Disha Patel
Eddy Arnold
Edmond J LaVoie
Joseph D Bauman
R S K Vijayan
Steven F Baker
P2860
P304
P3181
P356
10.1021/CB400400J
P577
2013-09-13T00:00:00Z